Rethink about growth-hormone therapy for critically ill patients

Lancet

Volumn 354, Issue 9188, 1999, Pages 1403-1404

  Bengtsson, B A ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL ILLNESS; DRUG MEGADOSE; HUMAN; MAJOR CLINICAL STUDY; NOTE; PRIORITY JOURNAL; SIDE EFFECT;

EID: 0033598609     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)00330-X     Document Type: Note

References (7)

1. Takala J., Ruokonen E., Webster N.R.et al. Increased mortality associated with growth hormone treatment in critical ill adults. N Engl J Med. 341:1999;785-792.
2. Ross R., Miell J., Freeman E.et al. Critical ill patients have high basal growth hormone with attenuated oscillary activity associated low levels of insulin-like growth factor-1. Clin Endocrinol. 35:1991;47-54.
3. Van den Berghe G., de Zegher F., Bouillon R. Acute and prolonged critical illness as different neuroendocrine paradigms. J Clin Endocrinol Metab. 83:1998;1827-1834.
4. Van den Berghe G., de Zegher F., Baxter R.C.et al. Neuroendocrinology of prolonged critical illness: effect of exogenous thyrotropin-releasing hormone and its combination with growth hormone-secretagogues. J Clin Endocrinol Metab. 83:1998;309-319.
5. Van den Berghe G., Wouters P., Weekers F.et al. Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness. J Clin Endocrinol Metab. 84:1999;1311-1323.
6. Bengtsson B.Å, Edén S., Lönn L.et al. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J Clin Endocrinol Metab. 76:1993;309-317.
7. Johannsson G., Rosén T., Bengtsson B.Å Individualised dose titration of growth hormone (GH) during GH replacement in hypopituitary adults. Clin Endocrinol. 47:1997;571-581.